Magnesium and Fentanyl in Preventing Reflex Hemodynamic Response to Endotracheal Intubation in Patients Aged 50 Years and Older

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This prospective, randomized, controlled trial aims to evaluate the effects of magnesium sulfate and fentanyl on the hemodynamic response to endotracheal intubation in surgical patients aged 50 years and older. A total of 75 patients will be enrolled and randomized into three groups: magnesium sulfate alone, magnesium sulfate plus fentanyl, and fentanyl alone. The primary outcome measures are changes in mean arterial pressure (MAP) and heart rate before and after intubation. Secondary outcomes include BIS, SEF, ST, TOF recovery times, intraoperative hemodynamic stability, and perioperative complications.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:

• Age ≥ 50 years

• Patients scheduled for elective surgery under general anesthesia

• Patients requiring endotracheal intubation with a single-lumen tube

• Provision of written informed consent

Locations
Other Locations
Turkey
Ankara Bilkent City Hospital, Department of Anesthesiology and Reanimation
NOT_YET_RECRUITING
Ankara
Ankara City Hospital
RECRUITING
Ankara
Contact Information
Primary
Fatmanur Gizem Özdemir, Resident
gzmlmz45@gmail.com
+905536069517
Backup
Aysun Postacı, MD, Prof.
aysunposta@yahoo.com
+905323520383
Time Frame
Start Date: 2025-10-10
Estimated Completion Date: 2026-01-30
Participants
Target number of participants: 75
Treatments
Experimental: Magnesium Sulfate Infusion Group (30 mg/kg)
Arm M: Magnesium sulfate (30 mg/kg IV over 10 min)
Experimental: Fentanyl Only Group (2 mcg/kg)
Participants will receive fentanyl 2 mcg/kg intravenously as a bolus
Experimental: Combined Magnesium Sulfate (30 mg/kg) and Fentanyl (2 mcg/kg) Group
Participants will receive magnesium sulfate 30 mg/kg intravenously over 10 minutes combined with fentanyl 2 mcg/kg intravenously
Related Therapeutic Areas
Sponsors
Leads: Ankara City Hospital Bilkent

This content was sourced from clinicaltrials.gov